Core Viewpoint - Ipsen has appointed Peter Guenter as a new Director on its Board, effective January 28, 2026, filling the vacancy left by Henri Beaufour [1][9]. Group 1: Appointment Details - Peter Guenter brings nearly 40 years of experience in the global pharmaceutical industry, having most recently served as CEO of Merck Healthcare from 2021 to 2025 [2]. - His previous roles include CEO at Almirall, where he focused on medical dermatology, and over 20 years at Sanofi, where he joined the Executive Committee in 2013 [2][3]. - Following this appointment, Ipsen's Board will consist of 14 directors, equally divided between men and women, including five independent directors and two employee representatives [3]. Group 2: Shareholder Meeting - A request for ratification of Peter Guenter's appointment will be presented at the next Shareholders' meeting, which will remain effective until the 2027 Shareholders' meeting [4]. Group 3: Company Overview - Ipsen is a global biopharmaceutical company focused on transformative medicines in oncology, rare diseases, and neuroscience, with nearly 100 years of development experience [5]. - The company operates in over 40 countries and partners globally to deliver medicines to more than 100 countries [5].

Market Overview - The global Bioprocess Containers Market is valued at USD 2.67 billion in 2024 and is projected to reach USD 9.24 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 16.7% from 2025 to 2032 [1] - Bioprocess containers are sterile, flexible containers used in biopharmaceutical manufacturing, replacing traditional stainless-steel bioreactors and storage vessels, offering advantages such as reduced cleaning requirements and lower contamination risks [5][6] Key Drivers - The market is driven by increasing demand for biologics, vaccines, and personalized medicines, necessitating flexible and scalable manufacturing solutions [6][17] - The adoption of single-use technologies is rising across all stages of bioprocessing, providing benefits like reduced cleaning validation and faster batch changeovers [8][21] Technological Advancements - AI is enhancing operational efficiency in the bioprocess containers market by optimizing workflows, predicting equipment failures, and improving quality control [2][4] - Innovations include the development of advanced multi-layer films with enhanced barrier properties and the integration of smart technologies for real-time monitoring [12][21] Market Segmentation - The market is segmented by type, application, and end-user, with 3D bioprocess containers expected to grow significantly due to their scalability for larger volumes [22][23] - Upstream processes are anticipated to demonstrate rapid growth, driven by the increasing complexity of cell culture and fermentation steps [26] Regional Insights - North America leads the market, projected to grow at a CAGR of 16.2%, driven by a robust biopharmaceutical industry and early adoption of single-use technologies [24][27] - The Asia Pacific region is expected to witness the fastest growth at a CAGR of 17.5%, fueled by expanding healthcare infrastructure and rising investments in biopharmaceutical R&D [28] Future Outlook - The bioprocess containers market is expected to continue expanding, driven by the increasing pipeline of biologics and advanced therapies, with a focus on sustainability and smart technologies [14][31] - The emphasis on supply chain resilience and the development of environmentally friendly materials will shape future innovations in the market [31]